{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:24:00Z","timestamp":1791257040560,"version":"4.1.0"},"reference-count":59,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Treatment advances for hematologic malignancies (HM) have dramatically improved life expectancy, necessitating greater focus on long-term cancer pain management. This study explored real-world patterns of opioid use among patients with HM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study identified adults diagnosed with HM from January 1, 2013 through December 31, 2019 using the Truven MarketScan Commercial Claims and Encounters database. Across several HM types, we described rates of high-risk opioid use (based on Pharmacy Quality Alliance measures) and opioid-related harms, including incident opioid use disorder (OUD) diagnoses and opioid-related hospitalizations or emergency department (ED) visits. We used multivariable Cox regression to generate adjusted hazard ratios and 95% confidence intervals comparing the risk of opioid-related harms between patients with versus without high-risk opioid use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our sample included 43,190 patients with HM. Median age at HM diagnosis was 54 years (interquartile range\u2009\u2009=\u2009\u200944\u201360). Most patients (61.9%) were diagnosed with lymphoma. Approximately half (49.2%) had an opioid dispensed in the follow-up period. Among all patients, 20.0% met criteria for high-risk opioid use, 0.9% had an OUD diagnosis, and 0.3% experienced an opioid-related hospitalization\/ED visit in follow-up. High-risk opioid use increased the risk of an OUD diagnosis by 3.3 times (p\u2009&lt;\u20090.0001) and an opioid-related hospitalization\/ED visit 4.2 times (p\u2009&lt;\u20090.0001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>High-risk opioid use was prevalent among patients with HM and significantly increased the risk of opioid-related harms. However, rates of opioid-related harms were low. These findings highlight the importance of continually monitoring pain and opioid use throughout HM survivorship to provide safe, effective HM pain management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552231210788","type":"journal-article","created":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T04:29:09Z","timestamp":1699504149000},"page":"1317-1329","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Patterns of prescription opioid use and opioid-related harms among adult patients with hematologic malignancies"],"prefix":"10.1177","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0632-6311","authenticated-orcid":false,"given":"Nadia A","family":"Nabulsi","sequence":"first","affiliation":[{"name":"Department of Pharmacy Systems, Outcomes and Policy, College of Pharmacy, University of Illinois Chicago, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa K","family":"Sharp","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Systems, Outcomes and Policy, College of Pharmacy, University of Illinois Chicago, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9559-0282","authenticated-orcid":false,"given":"Karen I","family":"Sweiss","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, University of Illinois Chicago, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pritesh R","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, University of Illinois Chicago, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7744-3518","authenticated-orcid":false,"given":"Gregory S","family":"Calip","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Systems, Outcomes and Policy, College of Pharmacy, University of Illinois Chicago, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd A","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Systems, Outcomes and Policy, College of Pharmacy, University of Illinois Chicago, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,11,9]]},"reference":[{"key":"bibr1-10781552231210788","unstructured":"Centers for Disease Control and Prevention (CDC). Prescription Opioids. 2022. Accessed April 23, 2023 from https:\/\/www.cdc.gov\/drugoverdose\/deaths\/prescription\/overview.html."},{"key":"bibr2-10781552231210788","unstructured":"Pharmacy Quality Alliance (PQA). 2022. PQA Opioid Measures. Accessed April 23, 2023 from https:\/\/www.pqaalliance.org\/opioid-measures."},{"key":"bibr3-10781552231210788","unstructured":"Centers for Disease Control and Prevention (CDC). 2021. Clinical Quality Improvement Opioid Measures. Accessed April 23, 2023 from https:\/\/www.cdc.gov\/opioids\/healthcare-admins\/pdf\/Clinical-Quality-Improvement-Opioid-Measures-508.pdf."},{"key":"bibr4-10781552231210788","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.1464"},{"key":"bibr5-10781552231210788","unstructured":"Pharmacy Quality Alliance (PQA). 2021. PQA medication safety measures. Accessed April 23, 2023 from https:\/\/www.pqaalliance.org\/medication-safety."},{"key":"bibr6-10781552231210788","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.1574"},{"key":"bibr7-10781552231210788","doi-asserted-by":"publisher","DOI":"10.7326\/M17-3065"},{"key":"bibr8-10781552231210788","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2559"},{"key":"bibr9-10781552231210788","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012509"},{"key":"bibr10-10781552231210788","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.8-6-567"},{"key":"bibr11-10781552231210788","volume":"7","author":"Wiffen PJ","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr12-10781552231210788","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1812850"},{"key":"bibr13-10781552231210788","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30839"},{"key":"bibr14-10781552231210788","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2019.05.019"},{"key":"bibr15-10781552231210788","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijnurstu.2016.11.003"},{"key":"bibr16-10781552231210788","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.15945"},{"key":"bibr17-10781552231210788","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaa122"},{"key":"bibr18-10781552231210788","unstructured":"American Society of Hematology. 2018. Statement on opioid use in patients with hematologic diseases and disorders. Accessed April 23, 2023 from https:\/\/www.hematology.org\/advocacy\/policy-news-statements-testimony-and-correspondence\/policy-statements\/2018\/opioid-use-patients-hematologic-diseases."},{"key":"bibr19-10781552231210788","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0323-4"},{"key":"bibr20-10781552231210788","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32736"},{"key":"bibr21-10781552231210788","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-154472"},{"key":"bibr22-10781552231210788","doi-asserted-by":"publisher","DOI":"10.1177\/1062860620944472"},{"key":"bibr23-10781552231210788","unstructured":"Pharmacy Quality Alliance (PQA). 2022. Measures overview. Accessed April 23, 2022 from https:\/\/www.pqaalliance.org\/measures-overview."},{"key":"bibr24-10781552231210788","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.publhealth.22.1.213"},{"key":"bibr25-10781552231210788","unstructured":"Truven Health Analytics. 2017. Truven Health MarketScan Research Databases. Accessed April 2023 from https:\/\/theclearcenter.org\/wp-content\/uploads\/2020\/01\/IBM-MarketScan-User-Guide.pdf."},{"key":"bibr26-10781552231210788","unstructured":"Centers for Disease Control and Prevention (CDC) and National Center for Health Statistics (NCHS). 2017. NCHS Urban-Rural Classification Scheme for Counties. Accessed April 23, 2023 from https:\/\/www.cdc.gov\/nchs\/data_access\/urban_rural.htm."},{"key":"bibr27-10781552231210788","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2017.10.010"},{"key":"bibr28-10781552231210788","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr6501e1"},{"key":"bibr29-10781552231210788","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0000000000002496"},{"key":"bibr30-10781552231210788","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2005.00072.x"},{"key":"bibr31-10781552231210788","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djz200"},{"key":"bibr32-10781552231210788","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2007.00401.x"},{"key":"bibr33-10781552231210788","doi-asserted-by":"publisher","DOI":"10.1016\/j.gerinurse.2018.10.003"},{"key":"bibr34-10781552231210788","volume-title":"Multivariate data analysis","volume":"3","author":"Hair JF","year":"1998"},{"key":"bibr35-10781552231210788","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.13431"},{"key":"bibr36-10781552231210788","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201900446"},{"key":"bibr37-10781552231210788","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11122037"},{"key":"bibr38-10781552231210788","volume":"375","author":"Newell LF","year":"2021","journal-title":"BMJ"},{"key":"bibr39-10781552231210788","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-007-0296-4"},{"key":"bibr40-10781552231210788","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2007.03.024"},{"key":"bibr41-10781552231210788","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-018-4583-5"},{"key":"bibr42-10781552231210788","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000001784"},{"key":"bibr43-10781552231210788","unstructured":"Agency for Healthcare Research and Quality (AHRQ). 2022. Rockville, MD. Healthcare cost and utilization project (HCUP). Accessed April 23, 2023 from https:\/\/www.ahrq.gov\/data\/hcup\/index.html."},{"key":"bibr44-10781552231210788","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0000000000000021"},{"key":"bibr45-10781552231210788","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-152-2-201001190-00006"},{"key":"bibr46-10781552231210788","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.7988"},{"key":"bibr47-10781552231210788","doi-asserted-by":"publisher","DOI":"10.5055\/jom.2015.0266"},{"key":"bibr48-10781552231210788","doi-asserted-by":"publisher","DOI":"10.1111\/papr.13098"},{"key":"bibr49-10781552231210788","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01250.x"},{"key":"bibr50-10781552231210788","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2010.12.008"},{"key":"bibr51-10781552231210788","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn700"},{"key":"bibr52-10781552231210788","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003116"},{"key":"bibr53-10781552231210788","doi-asserted-by":"publisher","DOI":"10.1159\/000495424"},{"key":"bibr54-10781552231210788","doi-asserted-by":"publisher","DOI":"10.1002\/pon.4218"},{"key":"bibr55-10781552231210788","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)33078-2"},{"key":"bibr56-10781552231210788","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-020-01528-7"},{"key":"bibr57-10781552231210788","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4929"},{"key":"bibr58-10781552231210788","unstructured":"Pharmacy Quality Alliance (PQA). 2022. Measure development. Accessed April 23, 2023 from https:\/\/www.pqaalliance.org\/measure-development."},{"key":"bibr59-10781552231210788","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02386"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552231210788","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552231210788","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552231210788","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:29:10Z","timestamp":1777688950000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552231210788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,9]]},"references-count":59,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1177\/10781552231210788"],"URL":"https:\/\/doi.org\/10.1177\/10781552231210788","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,9]]}}}